Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Once-daily therapies.

Dianne Carey1

  • 1National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Darlinghurst NSW 2010, Australia. dcarey@nchecr.unsw.edu.au

Journal of HIV Therapy
|July 4, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CYP2B6 polymorphisms and suicidal behaviour in people living with HIV treated with efavirenz-containing combination antiretroviral therapy: a global case-control study.

Frontiers in pharmacology·2026
Same author

Cardiometabolic impact of dolutegravir as second-line therapy: secondary analysis of a randomized controlled trial.

AIDS (London, England)·2026
Same author

Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2018
Same author

Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy.

AIDS (London, England)·2018
Same author

Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study.

Therapeutic drug monitoring·2017
Same author

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.

Clinical pharmacokinetics·2015

Simplifying combination antiretroviral therapy is crucial for HIV treatment success. Future HIV regimens may feature once-daily dosing for improved patient adherence and outcomes.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Public Health

Background:

  • Combination antiretroviral therapy (ART) is the standard for HIV treatment.
  • Complex regimens and toxicity hinder patient adherence, increasing treatment failure risk.

Purpose of the Study:

  • To review strategies for simplifying HIV treatment regimens.
  • To discuss the potential of once-daily dosing in future ART.

Main Methods:

  • Review of current ART simplification strategies.
  • Analysis of pharmacokinetic data for once-daily dosing potential.
  • Overview of antiretroviral drugs in clinical development.

Main Results:

  • Several ART drugs are available for once-daily administration.

Related Experiment Videos

  • Other drugs show pharmacokinetic promise for once-daily use.
  • New compounds supporting simplified dosing are in development.

    • Conclusions:

    • Simplifying HIV treatment regimens is essential for improving adherence.
    • Once-daily dosing represents a significant advancement in ART.
    • Future HIV treatment standards are likely to emphasize simplified, once-daily regimens.